1LikesBIO Unveils Preliminary Program for the 2012 BIO Convention in China
Event to take place in Shanghai, China, October 24-25, 2012
Press Release: Biotechnology Industry Organization (BIO)*–*8 hours ago
The BIO Convention in China | BIO
WASHINGTON--(BUSINESS WIRE)--
The Biotechnology Industry Organization (BIO) announces the 2nd annual BIO Convention in China, a partnering and investor conference that will bring together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities with China's emerging biotech sector. The event will take place October 24-25, 2012 in Shanghai, China.
“As China positions itself as a major global player in the international biotechnology arena, it has included biotechnology as one of the seven strategic priorities for scientific and technological development in its 12th Five-year Plan,” said Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development at BIO. "Through distinguished speakers, exemplary programming, compelling company presentations and exhibiting and networking opportunities, BIO China allows attendees to explore the vast business opportunities afforded by China’s emerging biotech sector.”
Dr. Michael Rosenblatt, M.D., executive vice president and chief medical officer for Merck, will provide one of two keynote addresses on October 25th. Directly following Dr. Rosenblatt’s keynote, Peng Wang, Ph.D., Chief Scientific Officer, Simcere will deliver his remarks. Governor Jon Huntsman, former U.S. Ambassador to China and Governor of Utah, will provide the third keynote address. Additional keynote speakers will be announced at a later date.
Panel sessions will highlight the latest issues and trends related to doing business in China. Preliminary program topics include the globalization of Chinese companies; innovation in generics and biosimilars; comparative legal systems in – U.S., Europe and China; R&D trends in China; trends in cancer research and regulatory review in China.
www.InvestorStemCell.com
- Investor Stemcell Forum
- Forum
- Investor StemCell Forums
- Public Stem Cell Companies
- Advanced Cell Technology
- ACT Off Topic
- China Bio Convention, Singapore Oct 24-25
Results 1 to 2 of 2
-
LinkBack
LinkBack URL
About LinkBacks- Bookmark & Share
- Tweet this thread
- Share on Facebook
-
08-07-2012 11:10 PM #1Achievements:
- Join Date
- Apr 2011
- Posts
- 1,086
- Location
- NJ
- Likes Given: 1148
- Likes Received: 4547
China Bio Convention, Singapore Oct 24-25
"Dry AMD is a form of macular degeneration with no approved drug treatment available to date,” said Dr. Carl Regillo who led the surgery. ACT's hESC-derived RPE cells could address the unmet medical need of combating dry AMD and other macular degenerations such as Stargardt's disease. We are looking forward to analysing the safety and efficacy data."
-
08-07-2012 11:13 PM #2Achievements:
- Join Date
- Apr 2011
- Posts
- 1,086
- Location
- NJ
- Likes Given: 1148
- Likes Received: 4547
Keynotes by Merck and China based Sincere who formed JV in July 2011
Merck News Item
"Dry AMD is a form of macular degeneration with no approved drug treatment available to date,” said Dr. Carl Regillo who led the surgery. ACT's hESC-derived RPE cells could address the unmet medical need of combating dry AMD and other macular degenerations such as Stargardt's disease. We are looking forward to analysing the safety and efficacy data."
Reply With Quote